Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations

Journal of Medicinal Chemistry

Volumn 52, Issue 4, 2009, Pages 1224-1228

  Butini, Stefania ^a   Brindisi, Margherita ^a   Cosconati, Sandro ^a,b   Marinelli, Luciana ^a,b   Borrelli, Giuseppe ^a   Coccone, Salvatore Sanna ^a   Ramunno, Anna ^a   Campiani, Giuseppe ^a   Novellino, Ettore ^a,b   Zanoli, Samantha ^a   Samuele, Alberta ^a   Giorgi, Gianluca ^c   Bergamini, Alberto ^d   Mattia, Michela Di ^e   Lalli, Silvana ^e   Galletti, Bruno ^e   Gemma, Sandra ^a   Maga, Giovanni ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e Sigma Tau SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6 ETHYL 6 [4 (PHENYLOXYMETHYL)PHENYL] 6,7 DIHYDROPYRROLO[1,2 D]PYRIDO[3,2 B][1,4]OXAZEPIN 7 ONE; 6 ETHYL 6 [4 [(3 CHLOROPHENYLOXY)METHYL]PHENYL] 6,7 DIHYDROPYRROLO[1,2 D]PYRIDO[3,2 B][1,4]OXAZEPIN 7 ONE; 8 C1TIBO; EFAVIRENZ; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME INHIBITION; ENZYMOLOGY; HUMAN; HUMAN CELL; MOLECULAR MODEL; MUTATION; STEREOCHEMISTRY;

ANTI-HIV AGENTS; CONSERVED SEQUENCE; DRUG RESISTANCE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MODELS, MOLECULAR; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 64349092076     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801395v     Document Type: Article

References (12)

1. De Clercq, E. HIV Inhibitors targeted at the reverse transcriptase. AIDS Res. Hum. Retrovirus 1992, 8, 119-134.
2. Kauffmann, G. R.; Cooper, D. A. Antiretroviral therapy of HIV-1 infection: Established treatment strategies and new therapeutic options. Curr. Opin. Microbiol. 2000, 3, 508-514.
3. Tomassi, C.; Van Nhien, A. N.; Marco-Contelles, J.; Balzarini, J.; Pannecouque, C.; De Clercq, E.; Soriano, E.; Postela, D. Synthesis, anti-HIV-1 activity, and modeling studies of N-3 Boc TSAO compound. Bioorg. Med. Chem. Lett. 2008, 18, 2277-2281.
4. Campiani, G.; Ramunno, A.; Maga, G.; Nacci, V.; Fattorusso, C.; Catalanotti, B.; Morelli, E.; Novellino, E. Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives. Curr. Pharm. Des. 2002, 8, 615-657.
5. Maga, G.; Ubiali, D.; Salvetti, R.; Pregnolato, M.; Spadari, S. Selective interaction of the human immunodeficiency virus type 1 reverse transcriptase nonnucleoside inhibitor efavirenz and its thio-substituted analog with different enzyme-substrate complexes. Antimicrob. Agents Chemother. 2000, 44, 1186-1194.
6. Campiani, G.; Morelli, E.; Fabbrini, M.; Nacci, V.; Greco, G.; Novellino, E.; Ramunno, A.; Maga, G.; Spadari, S.; Caliendo, G.; Bergamini, A.; Faggioli, E.; Uccella, I.; Bolacchi, F.; Marini, S.; Coletta, M.; Nacci, A.; Caccia, S. Pyrrolobenzoxazepinone derivatives as non-nucleoside HIV-1 RT inhibitors: Further structure-activity relationship studies and identification of more potent broad-spectrum HIV-1 RT inhibitors with antiviral activity. J. Med. Chem. 1999, 42, 4462-4470.
7. Locatelli, G. A.; Campiani, G.; Cancio, R.; Morelli, E.; Ramunno, A.; Gemma, S.; Hubscher, U.; Spadari, S.; Maga, G. Effects of drug resistance mutations L100I and V106A on the binding of pyrroloben-zoxazepinone nonnucleoside inhibitors to the human immunodeficiency virus type 1 reverse transcriptase catalytic complex. Antimicrob. Agents Chemother. 2004, 48, 1570-1580.
8. Maga, G.; Ramunno, A.; Nacci, V.; Locatelli, G. A.; Spadari, S.; Fiorini, I.; Baldanti, F.; Paolucci, S.; Zavatoni, M.; Bergamini, A.; Galletti, B.; Muck, S.; Hubscher, U.; Giorgi, G.; Guiso, G.; Caccia, S.; Campiani, G. The stereoselective targeting of a specific enzyme-substrate complex is the molecular mechanism for the synergic inhibition of HIV-1 reverse transcriptase by (R)-(-)-PPO464. J. Biol. Chem. 2001, 276, 44653-44662.
9. (a) Fattorusso, C.; Gemma, S.; Butini, S.; Huleatt, P.; Catalanotti, B.; Persico, M.; De Angelis, M.; Fiorini, I.; Nacci, V.; Ramunno, A.; Rodriguez, M.; Greco, G.; Novellino, E.; Bergamini, A.; Marini, S.; Coletta, M.; Maga, G.; Spadari, S.; Campiani, G. Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity. J. Med. Chem. 2005, 48, 7153-7165.
10. (b) Zanoli, S.; Gemma, S.; Butini, S.; Brindisi, M.; Joshi, B. P.; Campiani, G.; Fattorusso, C.; Persico, M.; Crespan, E.; Cancio, R.; Spadari, S.; Hiibscher, U.; Maga, G. Selective targeting of the HIV-1 reverse transcriptase catalytic complex through interaction with the "primer grip" region by pyrrolobenzoxazepinone non-nucleoside inhibitors correlates with increased selectivity towards drug-resistant mutants. Biochem. Pharmacol. 2008, 76, 156-168.
11. Das, K.; Bauman, J. D.; Clark, A. D., Jr.; Frenkel, Y. V.; Lewi, P. J.; Shatkin, A. J.; Hughes, S. H.; Arnold, E. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: Strategic flexibility explains potency against resistance mutations. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 1466-1471.
12. Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E. UCSF Chimera-A Visualization system for exploratory research and analysis. J. Comput. Chem. 2004, 25, 1605-1612.